Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 oct. 2021 09h00 HE | Source: Laidlaw Venture Partners

Algorithm Sciences, a Laidlaw Venture Partners Portfolio Company, Announces Board Appointments

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the appointment of Anthony Zook and Gary...
27 oct. 2020 08h30 HE | Source: Laidlaw Venture Partners

Laidlaw Venture Partners Continues Strategic Growth with the Addition of Zachary Shriver, Ph.D. and George Steinfels, Ph.D., MBA as Strategic Advisors for Key Operational Activities

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Zachary Shriver, Ph.D. and...
20 oct. 2020 08h30 HE | Source: Laidlaw Venture Partners

Laidlaw Venture Partners Continues Strategic Growth with Addition of Paul Korner, MD, MBA and Tony N. Hodges MD FCCP FACP, to its Investment and Operations Committee

NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of addition of Paul Korner, MD,...
25 août 2020 11h01 HE | Source: Laidlaw Venture Partners

Laidlaw Venture Partners Hosts Panel Discussion “Cutting Edge Perspectives on the Latest Developments in COVID-19 Vaccine Development Strategy”

Featuring Michael V. Callahan, MD, MSPH, DTM&H (U.K), Massachusetts General Hospital (MGH) Infectious Disease and Director, Clinical Translation and Mass-Casualty Therapeutics at the Vaccine...